Astellas Pharma introduces Astagraf XL for kidney-transplant patients

Drug designed for use with Genentech's CellCept, corticosteroids, Novartis' Simulect

NORTHBROOK, Ill. — Astellas Pharma has introduced a new drug for preventing the body from rejecting transplanted organs, the company said Thursday.

The drug maker announced the availability of Astagraf XL (tacrolimus) extended-release capsules in pharmacies. The drug is designed for use in kidney transplant patients with Genenetech's CellCept (mycophenolate mofetil) and corticosteroids, with or without induction of Novartis' Simulect (basiliximab).

"The availability of Astagraf XL marks a significant moment for the transplantation community, giving new adult kidney transplant recipients an additional option in their immunosuppressant care," Astellas Pharma US president James Robinson said. "Astellas has long been a leader in the field of transplant immunology, and we are proud to continue to advance care for transplant recipients."

Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

Login or Register to post a comment.